Advances in the treatment of triple-negative breast cancer with CDK4/6 inhibitors

ZHU Xiuzhi; CHEN Li; JI Lei; GAO Yu; WANG Zhonghua

doi:10.19401/j.cnki.1007-3639.2019.11.009

您当前的位置：

首页 >

文章列表页 >

Advances in the treatment of triple-negative breast cancer with CDK4/6 inhibitors

更新时间：2026-01-27

- Advances in the treatment of triple-negative breast cancer with CDK4/6 inhibitors
- China Oncology Vol. 29, Issue 11, Pages: 899-905(2019)
- 作者机构：
  
  复旦大学附属肿瘤医院乳腺外科，上海市乳腺肿瘤重点实验室，复旦大学上海医学院肿瘤学系,上海,200032
- 作者简介：
- 基金信息：
- DOI：10.19401/j.cnki.1007-3639.2019.11.009
  CLC：
- Published Online：11 December 2019，
  
  Published：11 December 2019
- 稿件说明：
移动端阅览
朱秀之, 陈　力, 纪　磊, 高　雨, 王中华. CDK4/6抑制剂治疗三阴性乳腺癌的研究进展[J]. 中国癌症杂志, 2019, 29(11): 899-905.

ZHU Xiuzhi, CHEN Li, JI Lei, et al. Advances in the treatment of triple-negative breast cancer with CDK4/6 inhibitors[J]. China Oncology, 2019, 29(11): 899-905.
朱秀之, 陈　力, 纪　磊, 高　雨, 王中华. CDK4/6抑制剂治疗三阴性乳腺癌的研究进展[J]. 中国癌症杂志, 2019, 29(11): 899-905. DOI： 10.19401/j.cnki.1007-3639.2019.11.009.

ZHU Xiuzhi, CHEN Li, JI Lei, et al. Advances in the treatment of triple-negative breast cancer with CDK4/6 inhibitors[J]. China Oncology, 2019, 29(11): 899-905. DOI： 10.19401/j.cnki.1007-3639.2019.11.009.

摘要

细胞周期的调控机制在肿瘤的发生、发展中发挥着重要作用。多项研究表明，在雌激素受体阳性、人类表皮生长因子受体阴性的乳腺癌患者中，细胞周期蛋白依赖性激酶4/6（cyclin-dependent kinase 4/6，CDK4/6）抑制剂具有较好的疗效，然而其在三阴性乳腺癌患者中的疗效仍需进一步探讨。Cyclin D-CDK4/6-INK4-Rb-E2F信号通路因具有调控细胞周期检查点的作用，被认为是乳腺癌潜在的治疗靶点。寻找三阴性乳腺癌与CDK4/6抑制剂关联的生物标志物，探究合理的药物配伍，筛选能从中获益的靶向人群，对临床工作具有重要意义。对CDK4/6抑制剂在三阴性乳腺癌的研究进展进行综述，探讨其应用前景及优化手段。

Abstract

The regulatory mechanism of cell cycle plays an important role in the occurrence and development of tumors. In recent years

a number of studies have shown that cyclin-dependent kinase 4/6 (CDK4/6) inhibitors have good efficacy in patients with estrogen receptor-positive

human epidermal growth factor receptor-negative breast cancer

but their efficacy in patients with triple-negative breast cancer is still controversial. Cyclin D-CDK4/6 -INK4-Rb-E2F signaling pathway is considered as a potential therapeutic target for breast cancer due to its role in regulating cell cycle check points. It is of great significance to explore the molecular markers related to CDK4/6 inhibitors for triple-negative breast cancer

guide rational drug combination

and screen the population of triple-negative breast cancer patient who can benefit from this drug. In this article

we reviewed the research progress of CDK4/6 inhibitors in triple-negative breast cancer

and discussed their application prospects and optimization methods.

关键词

Keywords

references

Views

4553

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

The progress of treatment for triple-negative breast cancer in the era of precision medicine

Expression of circRNA hsa_circ_0005320 in triple-negative breast cancer and its effect on cell proliferation

Latest research progress on tumor-infiltrating lymphocytes in HER2-positive and triple-negative breast cancer

Related Author

CAO Xiaoshan

CONG Binbin

ZHENG Xiaying

CHEN Junxia

JI Peng

Related Institution

Department of Breast Cancer Center, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Science

Department of Cell Biology and Genetics, Chongqing Medical University

AI问答

⁰